Advances of the Correlation between Driver Gene Status and Immunotherapy
in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2019.04.06
- Author:
Jie CHEN
1
;
Da JIANG
1
;
Fang HUANG
1
Author Information
1. The Forth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
- Publication Type:Journal Article
- Keywords:
Driver Gene;
Hyperprogression;
Immnotherapy;
Lung neoplasms
- MeSH:
Carcinoma, Non-Small-Cell Lung;
genetics;
immunology;
therapy;
Humans;
Immunotherapy;
methods;
Lung Neoplasms;
genetics;
immunology;
therapy;
Treatment Outcome
- From:
Chinese Journal of Lung Cancer
2019;22(4):233-238
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the checkpoint inhibitors targeted programmed cell death 1 (PD-1) and its ligand 1 (PD-1 ligand, PD-L1) achieved landmark significance in treating a variety of cancers including non-small cell lung cancer (NSCLC). However, current immunotherapy is not precise enough, only 15%-20% of the unselected patients can benefit from the therapy, and there is a possibility of hyperprogression (HP). Therefore, how to select the dominant population is crucial. Although many studies have emphasized the importance of PD-L1 and tumor mutation burden (TMB) and other indicators to guide immunotherapy, current PD-L1 expression level and mutation load cannot be used as a decisive and excluded predictive marker based on various obstacles. With the deepening of research, we found that there is a close relationship between lung cancer-driver gene mutation and aberrant activation of PD-1/PD-L1 signal pathways, and the correlation between gene mutation and immunotherapy efficacy has broad research value. This article will revolve around the above issues.
.
